CLAIMS

1. Use of idrabiotaparinux for the manufacture of a medicament useful for ~~the treatment and secondary prevention of thrombotic pathologies, wherein the use of idrabiotaparinux involves a decrease in the incidence of bleedings during said treatment~~ decreasing the incidence of bleedings during an antithrombotic treatment of a thrombotic pathology, compared with a treatment by either idraparinux or a vitamin K antagonist.

2. The use according to claim 1, wherein idrabiotaparinux is administered for up to 6 months.

3. The use according to claim 1 or claim 2, wherein the thrombotic pathology is venous thromboembolism.

4. The use according to any of claims 1 to 3, wherein the thrombotic pathology is deep venous thrombosis.

~~5. The use according to any of claims 1 to 4, wherein said medicament is useful for the treatment of venous thromboembolism and for the prevention of subsequent venous thromboembolic events.~~

~~6. The use according to any of claims 1 to 5, wherein the incidence of bleedings is decreased compared with a treatment by either idraparinux or a vitamin K antagonist.~~

~~7~~5. The use according to any of claims 1 to ~~6~~4, wherein the decrease in the incidence of bleedings is assessed after 6 months of treatment with idrabiotaparinux.

~~8~~6. The use according to any of claims 1 to ~~7~~5, ~~wherein the use of idrabiotaparinux involves a decrease in~~for decreasing the incidence of major bleedings.